Can Stereotaxis (STXS) Stock Reach $3.10?

Stereotaxis, Inc. (STXS) is a medical device company that designs and sells robotic systems, instruments, and information systems used in the interventional lab, best known for its robotic magnetic navigation technology for cardiac procedures. After a sharp multi-month decline that pushed shares below $1.00 in early November 2026, the stock has rebounded and now trades near $1.08. That still leaves a very large gap to the $3.10 central analyst price target examined here.

Key Takeaways

• The central target is $3.10, the arithmetic mean of four verified current analyst price targets, rounded from $3.125.
• At a recent price near $1.08, reaching $3.10 would require a rise of roughly 185% — a very large move.
• The four verified targets range from $3.00 to $3.50, and all carry Buy or Outperform-equivalent ratings.
• Support comes from early commercial traction for new products and analyst expectations of a potential commercial inflection in 2027.
• The biggest risks are continued revenue shortfalls, cash constraints, dilution, and the stock's recent slide toward $1.00.
• For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages.
• You can also explore Trending AI Robots for automated strategies that monitor changing market conditions.

Analyst Price Targets and Consensus View

Four credible, current price targets were reviewed. Citizens JMP (Daniel Stauder) set a $3.00 target on August 27, 2026; Lake Street (Frank Takkinen) set $3.00 on August 12, 2026; and TD Cowen (Josh Jennings) set $3.00 on August 11, 2026. Piper Sandler (Adam Maeder) holds a $3.50 target from May 13, 2026. Together these produce a mean of $3.125, rounded to a $3.10 central target, with a range of $3.00 to $3.50.

The striking feature is that the three most recent revisions were cuts, not raises. Following a second-quarter 2026 revenue miss and lowered company outlook, Citizens JMP, Lake Street, and TD Cowen each reduced their targets from $4.00–$5.00 to $3.00. Crucially, every analyst kept a Buy or Outperform-equivalent rating, describing the move as a model reset tied to near-term revenue and manufacturing constraints rather than a loss of confidence in the longer-term opportunity. The consistent $3.00 anchor reflects a shared view that commercialization is simply running later than previously modeled, while Piper Sandler's $3.50 stands as the relatively more optimistic entry.

Current Market Position and Path Toward the Target

With the stock near $1.08, the $3.10 central target implies upside of roughly 185% — a very large move by any standard. Context matters: STXS has fallen more than 70% over the past year and sits in the lower portion of a 52-week range of roughly $0.80 to $2.89. The path toward the target would therefore require not just a recovery of investor confidence but a genuine acceleration in commercial execution.

Stereotaxis generated about $32.4 million in revenue in 2025, up roughly 20% from the prior year, but remains deeply unprofitable, with trailing twelve-month revenue near $30 million and a net loss around $23.6 million. Analysts frame the investment case around a "commercial inflection" expected in 2027, meaning the stock is effectively being valued on future adoption of its robotics platforms rather than current financial results. Because the company is small and pre-profit, the stock price is highly sensitive to each quarter's revenue, order flow, and cash-burn figures.

What Could Support a Move Toward the Target

• New product traction: Analysts cite "green shoots" in commercial adoption of recently launched offerings as a basis for retaining Buy ratings despite the reset.
• Improving cash flow: Citizens JMP noted improving cash flow prospects among the reasons for its Outperform stance.
• Growth trajectory: Revenue rose about 20% in 2025, and the company is expected to grow further as its installed base expands.
• Unanimous bullish ratings: No current Hold or Sell ratings exist, reflecting a conviction that the valuation has already priced in much of the near-term disappointment.

What Could Prevent the Target From Being Reached

• Revenue misses and guidance cuts: The August 2026 downgrades were triggered by exactly these, and a repeat could force further target reductions.
• Cash and dilution risk: With a cash runway measured in months and multiple shelf registrations on file, equity raises could pressure the share count and price.
• Manufacturing constraints: Analysts explicitly flagged these as limiting near-term revenue even where demand exists.
• Persistent losses: An EPS (earnings per share) near negative $0.24 and negative profitability leave the stock dependent on future growth rather than current earnings.
• Listing-level risk: The recent dip below $1.00 keeps the stock near a round-number psychological threshold, which can dampen institutional interest.

Technical Levels and Market Structure

The 52-week range of roughly $0.80 to $2.89 defines the durable structure. After touching the low end near $0.80 in early November 2026, the stock reclaimed the $1.00 psychological level and traded above $1.14 intraday. The $1.00 area now functions as a meaningful round-number support level to watch, while the multi-month slide leaves a series of prior levels — including the $2.89 52-week high — well above the current price and far removed from the $3.10 target. Any sustained move toward the target would first require the stock to re-establish itself firmly above $1.00 and rebuild upward momentum.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, and the four targets used here were issued between May and August 2026, aligning with that timeframe. Investors should monitor quarterly earnings and revenue, any updates to guidance, new order and installation announcements, and cash-burn and financing activity, given the company's runway and dilution risk. Analyst revisions will also matter: the direction of the next round of target changes will signal whether the commercial inflection analysts expect for 2027 is materializing or slipping further.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, thinly traded name like STXS, such tools can help traders discover opportunities, monitor existing positions, and spot emerging trend shifts more efficiently than manual chart review alone. Explore the signals to complement your own research.

Final Assessment

Can Stereotaxis (STXS) reach $3.10? The target is a calculated mean of four Buy-rated analyst price targets spanning $3.00 to $3.50, not an official published consensus. It represents roughly 185% upside from the recent price near $1.08 — a very large move that would require a decisive commercial inflection, sustained revenue growth, and renewed investor confidence. The strongest support is the unanimity of bullish ratings and early signs of product traction, while the principal obstacles are recurring revenue shortfalls, manufacturing constraints, cash burn, and dilution risk. The next earnings report, guidance updates, and subsequent analyst revisions will be the clearest signals of whether the gap toward $3.10 begins to close or widens further.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations